NCT02141828View on ClinicalTrials.gov

A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

June 30, 2016

Conditions
LeukemiaAcute Myeloid LeukemiaAcute Lymphocytic LeukemiaAcute Leukemias
Interventions
DRUG

EPZ-5676

28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

21287

Johns Hopkins University, Baltimore

30322

Emory Children's Healthcare of Atlanta, Atlanta

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

80045

Children's Hospital Colorado, Aurora

90027

Childrens Hospital Los Angeles, Los Angeles

94143

University of California San Francisco Medical Center-Parnassus, San Francisco

02215

Dana Farber Cancer Institute, Boston

Unknown

The Hospital for Sick Kids, Toronto

Sponsors

Lead Sponsor

Epizyme, Inc.

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Epizyme, Inc.

INDUSTRY

NCT02141828 - A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | Biotech Hunter | Biotech Hunter